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InflammationCommercially available implantable needle-type glucose sensors for diabetes management are robust
analytically but can be unreliable clinically primarily due to tissue–sensor interactions. Here, we present
the physical, drug release and bioactivity characterization of tubular, porous dexamethasone (Dex)-
releasing polyurethane coatings designed to attenuate local inflammation at the tissue–sensor interface.
Porous polyurethane coatings were produced by the salt-leaching/gas-foaming method. Scanning elec-
tron microscopy and micro-computed tomography (micro-CT) showed controlled porosity and coating
thickness. In vitro drug release from coatings monitored over 2 weeks presented an initial fast release fol-
lowed by a slower release. Total release from coatings was highly dependent on initial drug loading
amount. Functional in vitro testing of glucose sensors deployed with porous coatings against glucose
standards demonstrated that highly porous coatings minimally affected signal strength and response
rate. Bioactivity of the released drug was determined by monitoring Dex-mediated, dose-dependent
apoptosis of human peripheral blood derived monocytes in culture. Acute animal studies were used to
determine the appropriate Dex payload for the implanted porous coatings. Pilot short-term animal stud-
ies showed that Dex released from porous coatings implanted in rat subcutis attenuated the initial
inflammatory response to sensor implantation. These results suggest that deploying sensors with the
porous, Dex-releasing coatings is a promising strategy to improve glucose sensor performance.
 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.1. Introduction
The dominant management strategy for blood sugar control in
type I diabetes mellitus involve a combination of blood glucose
monitoring by finger pricking and manual insulin delivery. These
strategies are often inadequate in cases where tight glycemic con-
trol is prescribed [1–4]. Consequently, there is a pressing need for a
closed-loop system in which real-time changes in glucose levels
monitored by a sensor are used to regulate automated insulin
delivery [1,2,4,5]. Unfortunately, contemporary implantable nee-
dle-type glucose sensors that could be used to manage insulin sup-
ply can behave unpredictably in vivo.
Often, a sensor that performs robustly and accurately in vitro
may upon implantation continue to work adequately, fail acutely,
show a steady drift, or exhibit a combination thereof. Interestingly,
upon post-removal testing, the sensor will regain proper function-
ality [6–8]. This observation suggests that the unpredictablebehavior of implanted sensors may be driven by the tissue–sensor
interaction and not by failures in the sensor itself.
Implanted glucose sensors are subject to a dramatically varying
tissue microenvironment over the 5–7 day period for which they
are approved for patient use. Upon implantation, the sensor is pre-
sented with hemostasis followed by immune cell recruitment and
inflammation, and finally the tissue gives way to a repair/remodel-
ing stage comprised of provisional matrix formation, fibrosis and
loss of vasculature. Several excellent reviews are available on this
topic [7,9]. Adequately surviving this sequela of events, often
referred to as the break-in period, has become an important design
criterion in the development of implantable glucose sensors.
Initial strategies to extend sensor functionality have focused on
preventing protein adsorption and cell attachment through the
incorporation of hydrogel coatings [10,11]. The emerging senti-
ment is that resistance to biofouling is necessary but not sufficient
to ensure proper sensor function. Numerical modeling and in vitro
studies have recently shown that increased glucose consumption
and enzymatic attack by immune cells during inflammation may
be one of the dominant factors negatively affecting glucose sensor
function [12–14].
Table 1
Porogen and Dex added to stock polymer solution to produce coatings with different
porosities and Dex loadings.
Intended % porosity Porogen (g) Intended wt.% Dex Dex (mg)
90 1.5 2.9 180
60 1.0 1.4 90
30 0.5 0.7 45
4630 S.G. Vallejo-Heligon et al. / Acta Biomaterialia 10 (2014) 4629–4638Currently there exist essentially two schools of thought towards
addressing acute inflammation: management and attenuation.
Proponents of inflammation management view inflammation as a
necessary step to achieve a stable and acceptable tissue bed for
an implanted glucose sensor. Approaches that manage acute
inflammation are inherently more complex and employ strategies
to guide immune cell phenotype and cytokine production [15,16].
Attenuation of inflammation contends that the benefits of mini-
mizing the deleterious effects of acute inflammation on sensor
function outweigh the potential advantages of engineering the tis-
sue response. One strategy for the attenuation of acute inflamma-
tion involves the local release of anti-inflammatory mediators such
as nitric oxide, non-steroidal anti-inflammatory drugs and gluco-
corticoids [17–19].
Recent reports have shown that localized delivery of dexameth-
asone (Dex) reduces of anomalous sensor effects that arise from
inflammatory cell invasion to the surface of an indwelling sensor
[20]. Dex is a potent glucocorticoid associated with diminished
activation of immune cells and up-regulation of anti-inflammatory
cytokines [11,21–24]. However, localized delivery of Dex is often
accompanied by decreased vascularity at the sensor–tissue inter-
face [25]. Previous studies have also demonstrated that highly por-
ous coatings of controlled structure (50–75 lm pore size) could be
used to increase vascular perfusion of the tissue bed [26,27]; to our
knowledge researchers have yet to explore the combination of
these two proven effects as a strategy to improve indwelling glu-
cose sensor function.
Our goal is to incorporate Dex release as an inflammation atten-
uation component into a textured coating designed to increase
long-term vascular density around implanted sensor leads. There-
fore, the current study looked at the possibility of combining pro-
angiogenic texturing with anti-inflammatory Dex release.
Here, we present the fabrication and characterization of Dex-
releasing porous polyurethane coatings for needle-type glucose
sensors. Pore size, porosity and coating thickness of the porous
polyurethane coatings were evaluated by scanning electron
microscopy (SEM) and micro-computed tomography (micro-CT).
Signal strength and response time of sensors deployed with porous
coatings was demonstrated using glucose standards. Drug release
from porous coatings was monitored over 2 weeks as a function
of initial loading and coating porosity. Bioactivity of the released
drug was demonstrated by monitoring the Dex-mediated, dose-
dependent apoptosis of human peripheral blood derived mono-
cytes in culture. Acute animal studies were used to determine
the appropriate Dex payload for the implanted porous coatings.
Pilot short-term animal studies showed that Dex released from
porous coatings diminished the initial inflammatory response to
glucose sensor implantation. These results suggest that deploying
sensors with these porous, Dex-releasing coatings is a promising
strategy to improve glucose sensor performance.2. Methods
2.1. Fabrication of Dex-releasing porous coatings
Porous coatings were fabricated by the gas-foaming/salt-leach-
ing technique described previously [27]. Briefly, a 6.5 wt.% solution
of polyurethane was prepared by dissolving Tecoflex 93A pellets
(Lubrizol Technologies) in a solution of 25:75 ethanol/chloroform.
Dex (Sigma, D1756) was dissolved in the polymer solution and stir-
red until clear. Sieved (50–75 lm) ammonium bicarbonate salt
particles (MP Biomedicals, 150107) were added to the polymer
solution and homogeneously mixed. Table 1 lists the amount of
Dex and ammonium bicarbonate porogen added to polyurethane
stock solutions to produce various specimen compositions.Dex-free porous and non-porous coatings were fabricated either
by respectively not adding Dex or ammonium bicarbonate porogen
to the polymer solution.
Polymer films were dip-coated onto copper wire mandrels (Bel-
den, 20 AWG) and allowed to dry for 1 h. Films were porated by
placing the polymer-coated mandrels into deionized water for
5 min at 90 C to allow gas-foaming/salt-leaching to occur. Porated
films were then quickly quenched in 4 C deionized water for
20 min. Films were allowed to dry in overnight in a desiccator,
and cut to a length of 1.5 cm in order to fit over the sensing tips
of Medtronic MiniMed SOF-SENSOR™ sensors (Fig. 1A).
2.2. Scanning electron microscopy
A vacuum sputter coater (Denton Desk IV) was used to deposit
10 nm gold layer on the surface of the porous coatings. SEM images
of the porous coating surfaces and cross-sections were analyzed
using ImageJ. A length measurement tool was generated based
on the ratio of pixels per scale bar length of each image. Images
were standardized to cover a 0.5 mm2 area of the coatings. Using
the measurement tool, the major axis of each pore on the selected
surface was measured (Fig. 1B). Cross-sectional images were used
to measure the thickness of the coatings at the positions high-
lighted (Fig. 1C).
2.3. Micro-computed tomography
Porous coatings were soaked in Lugol’s Iodine (EMS Cat. No.
26055) for 3 days and were vacuum dried overnight. Samples were
evaluated using a Nikon XTH 225 ST micro-CT scanner. The X-ray
source was set to 80 kV and 120 lA, spot size < 3 lm, and rotation
step 0.5. An exposure time of 708 ms was set for each X-ray
image. Four X-ray images were then averaged to obtain one 2-D
projection. After acquisition, 2-D projections were reconstructed
using CT Agent software to provide axial picture cross-sections.
After reconstruction, the data was converted into 2000 16-bit pic-
ture files with a resolution of <3 lm per pixel. Complete volumes
were rendered in Avizo Fire 8.0. Sub-volumes consisting of 500
z-stack images were selected for porosity evaluation. Sample
porosity was calculated as the ratio of void to solid volume.
%Porosity ¼ Void VolumeCoating i
Volid VolumeCoating i þ Solid VolumeCoating i  100%2.4. Differential scanning calorimetry (DSC)
Differential scanning calorimetry (DSC) (PerkinElmer, Diamond
DSC N5360020) was employed to determine the physical state of
Dex in the polyurethane coatings. Pre-weighed 10 mg samples of
Dex-loaded porous coatings were placed into aluminum pans and
loaded into the sample chamber. Untreated Dex powder (Sigma,
D1756) samples were used as controls. Control samples weighed
0.5 mg to match the amount of Dex in contained in the 10 mg
Dex-loaded porous coating samples. The sample chamber was
purged with nitrogen to prevent air oxidation of the samples at
high temperatures. Samples were kept at 50 C for 10 min during
(A) (B) (C) 
Fig. 1. Pictures and ESEM images of porous coatings created via the salt-leaching/gas-foaming technique. (A) Picture of the Medtronic MiniMed Sof-Sensor™ with and
without highly porous Dex-releasing coatings. (B) ESEM of exterior surface and (C) cross-section of 90% porosity/2.9 wt.% Dex coatings. Arrows indicate pore diameters (B)
and coating thickness (C). (n = 6.).
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10 C min1 until a temperature of 400 C was reached. The degree
of Dex crystallinity was determined by measuring the characteris-
tic endothermic peak of Dex at 269 C.
2.5. High-performance liquid chromatography
Dex solution concentrations were determined using high-per-
formance liquid chromatography (HPLC) (Waters 2690) and a dual
absorbance UV detector (Waters 2487). The isocratic mobile phase
consisted of 42% acetonitrile and 58% water with a flow rate of
1 ml min1. Samples of 50 ll were injected directly and pumped
through an Omnisphere 5 C18 Column. Dex was detected using a
UV detector at 246 nm. The retention time of Dex was 3.7 min.
Dex solution concentration was determined from a standard curve
of Dex in PBS from 1 to 100 lg ml1.
2.6. Dex release studies
Coatings were placed into microcentrifuge tubes containing
1.5 ml of PBS (pH 7.4) at 37 C. Coatings were placed into fresh
1.5 ml PBS solutions every 24 h for a period of 2 weeks. Daily drug
release samples were stored at 4 C in the dark until analysis. Sam-
ples were thawed at room temperature and injected into the HPLC
system and the Dex concentration was determined as described
above.
To evaluate possible topographical changes due to the depletion
of Dex, coatings before and after the 2 week release study were
imaged by environmental scanning electron microscopy (ESEM)
(wet mode). Captured images were processed as described above
to calculate average thickness and pore size.
2.7. Dex loading efficiency
Pre- and post- gas-foamed coatings, and coatings after drug
release studies were completely dissolved in 1 ml chloroform.
Solutions were then injected into the HPLC and the Dex concentra-
tion was determined as described above.
2.8. Sensor response
Medtronic MiniMed SOF-SENSOR™ glucose sensors, MiniLink™
transmitters, and Transmitter Utility software package were gra-
ciously supplied by Medtronic MiniMed (Northridge, CA). Bare sen-
sors were hydrated for 2 h in PBS (37 C, stirred) and then dipped
sequentially in 100, 200, 400 and 0 mg dl1 glucose in PBS (37 C,
stirred) to obtain a calibrated baseline sensor response. Dex-loadedporous coatings were subsequently placed over the sensor tips and
subjected to a glucose challenge with 100, 200, 400 and 0 mg dl1
of glucose. Dex-free non-porous films served as controls.
Sensor response time and signal attenuation to glucose chal-
lenge were used as metrics to evaluate sensor function. Sensor
response times were calculated as the time for the sensor to
achieve 90% of its steady-state calibration current for a given test
interval. Attenuation was calculated as follows:
Attenuation % ¼ 1 Sensor CurrentChallenge Interval
Sensor CurrentCalibration Interval
 
 100%2.9. Peripheral blood derived human monocyte isolation
Human monocytes were isolated from 100 ml of EDTA-treated
blood drawn from healthy volunteers (n = 12). Using a hypotonic
density centrifugation method, buffy coats were collected from
the interphase of Histopaque 1077 (Sigma, 10771). After separa-
tion, mononuclear cells were washed twice with complete RPMI
1640 medium. Subsequently, untouched monocytes were nega-
tively selected using magnetic beads (Dynabeads, Life Technolo-
gies). Enriched monocytes were then incubated in RPMI 1640
medium supplemented with 10% (v/v) heat-inactivated AB serum,
50 lm 2-mercaptoethanol, 1 mM sodium pyruvate, 10 mM Hepes,
4.5 g l1 glucose, and 1% antibiotic/antimycotic solution. All cul-
tured reagents used had endotoxin levels of <0.01 ng ml1 LPS.
The isolated monocyte suspension was adjusted to a concentration
of 1  106 cells ml1. The viability of the monocytes was >95% as
determined by Calcein AM intracellular stain and purity was
>90% as assessed by CD14+ marker expression using flow cytomet-
ric analysis.
2.10. Dex-treated media preparations for apoptosis assays
Two apoptosis studies were conducted (i) to investigate if Dex
released from porous coatings retained its bioactivity after gas-
foaming/salt-leaching; and (ii) to show the dose-dependent effect
of Dex released from porous coatings on isolated monocytes.
For Dex bioactivity studies, 90% porous coatings loaded with
1.4 wt.% Dex were placed in RPMI for 24 h at 37 C allowing Dex
to be released into the media, the coatings were then moved to a
second set of fresh media for another 24 h, and then to a third
set of fresh media for another 24 h. This yielded media samples
with Dex released from coatings after 24, 48 and 72 h. Dex concen-
trations from these solutions were determined by HPLC. Equivalent
‘‘Dex-spiked media’’ solutions were made by spiking RPMI media
with concentrations equal to that of the Dex released from 90%
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Untreated media and media treated with Dex-free porous coatings
served as controls.
For Dex dose-dependent studies, 90% porous coatings loaded
with 0.7, 1.4 and 2.9 wt.% Dex were incubated in RPMI media as
described above for 24, 48 and 72 h. These solutions were then
used to culture isolated monocytes. Untreated media and Dex-free
porous coatings served as controls.
2.11. Annexin-V apoptosis assays
For both Dex apoptosis studies, monocytes were resuspended to
a density of 1  106 cells ml1 in treated and untreated media
immediately after isolation. Cells were plated in 6-well tissue cul-
ture plates. Cell samples from each well were collected every 24 h
for a period of 3 days and cultured at 37 C under 5% CO2. During
sample collection, cell medium was replaced by suspending mono-
cytes to a concentration of 1  106 cells ml1 concentration in new
treated or untreated media, respectively.
Up-regulation of phosphatidylserine (PS) receptor expression
was detected via Annexin-V antibody staining in treated peripheral
blood derived human monocytes. For staining, samples were kept
in ice washed twice in staining medium (ice-cold PBS supple-
mented with 10% FBS and 1% sodium azide). Monocytes were
directly labeled with APC-mouse mAb to CD14+(Invitrogen,
MHCD1405) and Annexin-V FITC to PS (Invitrogen, A13199). APC
and FITC-conjugated murine IgG mAbs of unrelated specificities
were used as negative stain controls. Annexin-V positive controls
were created by treating U937 cells with camptothecin at a con-
centration of 4 lg ml1 for 4 h. After staining, suspended cells were
kept in ice and protected from light until Annexin-V and CD14+
expression was analyzed by flow cytometry analysis.
2.12. Animal studies
2.12.1. Preparation of implants
Medical-grade Tygon tubing (formulation S-54-HL Saint-Gob-
ain, Courbevoie, France) was selected for testing of the foreign
body response (FBR). Tygon implants were of similar dimensions
(1.5 cm long and 0.8 cm outer diameter) andmechanical properties
to the tips of the Medtronic MiniMed SOF-SENSOR™. Dex-free and
Dex-loaded 90% porous coatings were slid onto Tygon implants.
The coatings fitted snugly over the Tygon tubing and did not need
further affixing. Bare and coated implants were sterilized with eth-
ylene oxide and allowed to out-gas for at least 7 days prior to
implantation. Bare Tygon tubing was used as a positive control
because Tygon is a silicone known to undergo fibrous encapsula-
tion when subcutaneously implanted [28].
2.12.2. Implantation procedure
All National Institutes of Health guidelines for the care and use
of laboratory animals (NIH Publication No. 85–23 Rev. 1985)
were observed. Approval for these studies was granted by the
Institutional University Animal Care and Use Committee at Duke
University prior to initiation of these studies. Sprague–Dawley rats
(200–300 g; CD-type, Charles River Labs, Raleigh, NC) were shaved
and prepped prior to surgery. After anesthesia induction with 3%
isoflurane in oxygen, the dorsal areas were shaved and the skin
prepped with chlorhexidine and alcohol three times. The rats were
placed in the prone position and a sterile field was created over
the dorsum. All implants were inserted via a trocar introducer. A
sterile 12-gauge needle was used to access the subcutaneous plane;
implants were inserted into the needle and advanced into the rat
subcutis using a plunger. The needle and plunger were simulta-
neously drawn back while the implant stayed in the desired site.
The minimal cutaneous wound did not require primary closure.2.12.3. Dex systemic effects
A pilot study was conducted in order to assess the systemic
in vivo effects of coated implants loaded with Dex. Porous coatings
that were Dex-free or contained 0.7, 1.4 and 2.9 wt.% Dex were
implanted in the dorsal subcutis of rats (n = 2 for each treatment).
Uncoated Tygon tubing was also implanted. All samples were
explanted 14 days post-implantation. Systemic Dex effects were
monitored by noting the rat’s weight and overall health every
3 days for the duration of the study, and by evaluating the tissue
response to uncoated Tygon.
2.12.4. Pilot evaluation of Dex-releasing coatings
Samples of 90% porous coatings with 0.7 wt.% Dex, which did
not exhibit system effects, were implanted in the dorsal subcutis
of rats along with Dex-free 90% porous coatings and bare Tygon
controls. Samples were explanted 3 days post-implantation.
2.13. Evaluation of histological samples
Tissue samples were flash frozen using liquid nitrogen immedi-
ately upon explantation and kept at 80 C. Serial cryosections of
10 lm thickness were cut and stained with hematoxylin and eosin
(H&E) to monitor inflammation. Cell nuclei stained purple while
the connective tissue surrounding the implant stained pink.
2.14. Statistical Analysis
All data are presented as means ± standard errors of the mean
(±SEM). Coating pore size, thickness and porosity results were
compared using a one-way ANOVA followed by Tukey’s HSD tests
for all samples (P < 0.05). Sensor functionality and drug release
were analyzed using two-way repeated-measures ANOVA followed
by Tukey’s HSD post hoc test (P < 0.05). Annexin-V apoptosis assay
results were analyzed using a two-way repeated measures ANOVA.
Lilliefors test on apoptosis data confirmed data normality, while a
Maulchy correction was performed since the data violated Maul-
chy’s sphericity test (unequal variances). Tukey’s HSD was used
for post hoc tests and the threshold for significance was P < 0.05.3. Results
3.1. Coating pore size, thickness and porosity
Fig. 1A shows a bare glucose sensor (left) and a sensor with a
90% porous coating (right). Coatings fit snugly over the sensor tip
and were porous throughout. Fig. 1B and C are SEM images show-
ing the porous microstructure and coating cross-section. Fig. 2
shows micro-CT volume renderings of the solid (Fig. 2A–D) and
corresponding void (Fig. 2E–H) spaces of a Dex-free 90% porous
coating, and Dex-loaded 90%, 60% and 30% porosity coatings. Total
void volume and interconnected void regions represented by indi-
vidual colors in Fig. 2E–H clearly diminished with decreasing
porosity.
Table 2 lists the average coating thickness and pore size mea-
sured by SEM and the coating percentage porosity calculated by
micro-CT for specimens that were intended to generate porosities
of 90%, 60% and 30%. A Dex-free 90% porosity specimen was
included for comparison. Coating thickness increased significantly
with decreasing porogen content, but no statistical difference in
average pore diameter was found across these specimen types.
The average percentage porosity measured by micro-CT closely
mirrored the intended specimen porosities of 90%, 60% and 30%.
The inclusion of Dex at the highest 2.9 wt.% loading did not signif-
icantly affect pore structure, porosity or coating thickness when
compared to porous Dex-free coatings.
30 % Porosity 2.9 wt%
Dex
90 % Porosity - 0 wt%
Dex
(A) (B) (C) (D) 
(E) (F) (G) (H) 
60 % Porosity  2.9 wt% 
Dex
90 % Porosity  2.9 wt% 
Dex
Fig. 2. Representative micro-CT images of porous coatings created via the salt-leaching/gas-foaming technique with decreasing porogen fraction. The images show coatings
of different morphologies created by varying the ammonium bicarbonate porogen concentration: (A,B) 90%, (C) 60% and (D) 30%. Addition of Dex did not disrupt scaffold
structure of (A) 0 wt.% Dex and (B–D) 2.9 wt.%. Corresponding 3-D volume renderings of porous structures are also shown, individual colors represent interconnected void
regions of coatings (E–H). (n = 6.).
Table 2
Physical characteristics of porous Dex-releasing coatings (n = 6).
Intended
composition
Thickness
(lm)
Pore diameter
(lm)
Measured porosity
(%)
Porosity
%
Dex
(wt.%)
90 0 85.3 ± 7.5 75.8 ± 10.1 86.2 ± 2.6
90 2.9 80.6 ± 8.3 70.4 ± 13.5 85.4 ± 4.1
60 2.9 130.5 ± 9.3* 76.8 ± 12.3 55.7 ± 9.8*
30 2.9 205.9 ± 17.9*# 72.8 ± 14.9 38.4 ± 3.7*
* Denotes P < 0.05 or less compared to 90% porosity/2.9 wt.% Dex coatings.
# Denotes P < 0.05 or less compared to 60% porosity/2.9 wt.% Dex coatings.
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DSC was employed to determine whether Dex loaded into coat-
ings was present in a molecularly dissolved state or was seques-
tered as crystals. The dashed lines in Fig. 3A and B show the100 150 200 250 300 350
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Fig. 3. Differential scanning thermographs of Dex-loaded porous coatings. Dex is found
increased from 0.7 to 2.9 wt.% Dex. Dex is found in a similar crystalline state in scaffo
amounts are listed in Table 3. (B) Changes in coating porosity did not affect crystal statcharacteristic exothermic melting of bulk Dex crystals (dashed
lines) at 269 C. This peak was absent in all Dex-loaded polymer
coatings (solid and dotted lines). These results suggest that Dex
was highly soluble in the polyurethane matrix and was not seques-
tered in a crystallized form.
3.3. Dex loading and retention after gas-foaming
Table 3 lists the Dex loading before (intended) and after the
salt-leaching/gas-foaming step (retained) for the coating formula-
tions used in the Dex release studies. The wt.% Dex retained after
gas-foaming correlated directly to the initial Dex loading, while
the percentage of Dex retained after the gas-foaming/salt-leaching
step for all groups averaged 79.7 ± 2.5% (mean ± SEM).
3.4. Dex release
Fig. 4 presents the 2 week in vitro release profile of Dex from
90% porous coatings prepared with 0.7, 1.4 and 2.9 wt.% Dex100 150 200 250 300 350
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in an amorphous state within the scaffolds. (A) Initial loading amounts of Dex were
lds with high (2.9 wt.%) and low (0.7 wt.%) initial loading amounts. Actual loading
e of Dex within scaffolds. (n = 6.).
Table 3
Loading efficiency and release summary of Dex incorporated into porous polyurethane coatings by salt-leaching/gas-foaming method (n = 10).
Intended sample
composition
Dex retained after foaming Average release rate (lg/day) Dex retained after 14 day release
(wt.%)
Porosity % Dex (wt.%) wt.% lg First week release (1–7 days) Second week release (8–15 days) wt.% lg
90 0.7 0.56 ± 0.07 305 ± 35 27.4 ± 2.9 7.2 ± 1.4 0.09 ± 0.07 48 ± 38
90 1.4 1.07 ± 0.09* 555 ± 46* 55.7 ± 5.9* 11.2 ± 2.3 0.17 ± 0.08* 87 ± 41*
90 2.9 2.10 ± 0.38*# 914 ± 163*# 93.9 ± 13.0*# 15.4 ± 6.1 0.32 ± 0.08*# 138 ± 34*#
60 2.9 2.41 ± 0.30 1195 ± 149 107.8 ± 16.4 27.2 ± 2.9 0.38 ± 0.16 189 ± 80
30 2.9 2.51 ± 0.32 1791 ± 230 142.5 ± 30.5 32.5 ± 3.6 0.44 ± 0.20 316 ± 143
* Denotes P < 0.05 or less compared to 0.7 wt.% Dex/90% porosity coatings.
# Denotes P < 0.05 or less compared to 1.4 wt.% Dex/90% porosity coatings.
(A) (B) 
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 90% Porous- 2.9 wt % Dex
60% Porous- 2.9 wt % Dex
30% Porous- 2.9 wt % Dex
Time (days)
Fig. 4. Cumulative release of Dex from porous coatings. (A) Initial loading amounts of Dex (0.7, 1.4 and 2.9 wt.%) and (B) original porogen content (90, 60 and 30% porosity)
were varied. Dex release from coatings shows a high dependency on initial loading. ⁄P < 0.05 or less compared to highlighted treatments. (n = 10.).
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with 2.9 wt.% Dex loadings (Fig. 4B). Overall, the cumulative Dex
release increased significantly with the amount of Dex payload.
In each case, a fast release rate was observed for days 1–7, followed
by a slow release rate for days 8–15 (Table 3). Release rates for
days 1–7 increased with increasing Dex payload, either by increas-
ing the wt.% Dex for a constant percentage porosity (Fig. 4A), or by
decreasing the percentage porosity for a constant wt.% Dex
(Fig. 4B). Week 2 release rates also followed the same trend but
the effect was less pronounced and not significant. The last column
in Table 3 lists the wt.% Dex that remained in the coatings after
14 days of release. The percentage retained after 14 days averaged
16.0 ± 0.9% (mean ± SEM) over all specimens, again bearing no
relationship to the percentage porosity. Moreover, SEM imaging
of 90% porous coatings before and after 14 days of Dex release
showed that the coating thickness and porosity was unaltered
(data not shown), which one would expect for solubilized small
molecule release from a non-degradable polymer.3.5. Sensor response time and signal attenuation
Fig. 5A and B show the in vitro responses of bare sensors and
sensors fitted with porous coatings to step increases glucose con-
centration. Table 4 lists the corresponding sensor response times
and percentage signal attenuations. All signals for sensors
deployed with 90% coatings were superimposed directly over the
bare sensor traces, and exhibited only slight increases in response
times and signal attenuation regardless of wt.% Dex loading. How-
ever, sensors fitted with non-porous coatings, 60% and 30% poros-
ity films showed significantly increased response times and signalattenuation compared to base sensors. Clearly, the 90% porous
coatings are best suited for use in sensors.
3.6. Bioactivity of Dex-releasing porous coatings
Fig. 6 displays the percentage of Annexin-V positive (i.e. apop-
totic) monocytes after exposure to Dex-releasing 90% porous coat-
ings for 24, 48 and 72 h. The 2.9 wt.% Dex coatings significantly
showed the highest percentage of Annexin-V positive monocytes
at 24, 48 and 72 h, with 25.5%, 49.34% and 65.5% cells being apop-
totic, respectively. A significant dose dependence of wt.% Dex at 48
and 72 h was observed. Apoptosis of monocytes cultured in media
treated with Dex-free porous coatings was similar to the baseline
level of apoptosis in untreated media. Finally, identical assays per-
formed with Dex-spiked media exhibited equivalent levels of
apoptosis as those using media from Dex released for coatings,
showing that the gas-foaming step had no effect on Dex bioactivity
(data not shown).
3.7. Pilot animal testing of Dex-releasing coatings
After 14 days, rats implanted with 2.9 wt.% Dex porous coatings
exhibited an 11–16 wt.% decrease as well as atrophy and thinning
of the dermal tissue, whereas rats implanted with 1.4 wt.% Dex
porous coatings did not exhibit any external signs of adverse Dex
effects. However, histological examination of bare positive control
implants showed an impaired inflammatory response when com-
pared to controls from rats implanted with Dex-free coatings (data
not shown). Rats implanted with 0.7 wt.% Dex porous coatings
were able to mount an appropriate immune response to positive
control implants, and showed no external signs of systemic Dex
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Fig. 5. Response of sensors with scaffolds of (A) varying porosities and (B) varying Dex loading concentrations compared to the response of bare sensors (without coatings)
and sensors with non-porous coatings. Sensors were subjected to a glucose challenge by exposing them to a series of glucose concentrations in the following order: 0, 100,
200, 400 and 0 mg dl1 in PBS at 45 min intervals at 37 C in stirred conditions. Decreasing coating porosity resulted in increased sensor response time and attenuation, while
changes in Dex loading did not affect the sensor signal when compared to bare sensors. Data presented are representative traces of six independent tests (n = 6).
Table 4
In vitro response of sensors deployed with Dex-releasing polyurethane porous coatings (n = 6).
Sample composition Time (min) to reach 90% steady state current % Attenuation 400? 0a Interval
Porosity % Dex (wt.%) 0? 100a 100? 200a 200? 400a 400? 0a
Bare sensor 5 ± 2 7 ± 2 10 ± 4 15 ± 6 6.5 ± 1.8
90 2.9 8 ± 3 7 ± 3 17 ± 3 24 ± 7 8.6 ± 1.9
60 2.9 17 ± 10 >45b*# >45b*# >45b*# 24.8 ± 6.9
30 2.9 >45b*#& >45b*# >45b*# >45b*# 49.7 ± 13.4*#
Non-porous coating >45b*#& >45b*# >45b*# >45b*# 92.5 ± 3.5*#
a Glucose challenge (mg dl1).
b Time exceeded experimental interval.
* Denotes P < 0.05 or less compared to bare sensor.
# Denotes P < 0.05 or less compared to 90% Porosity/2.9 wt% Dex coatings.
& Denotes P < 0.05 or less compared to 60% porosity/2.9 wt.% Dex coatings.
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Fig. 6. Dose Response of Human Peripheral Blood Derived Monocytes to Dexreleased from porous coatings. Monocytes were incubated in medium treated with porous
coatings ranging form 0.7- 2.9 wt % in initial Dex loading. Dexreleased from scaffolds induced apoptosis of monocytes in a dose and time dependent manner. There was a
strong dose dependency on monocyte apoptosis and initial Dex coating loading after 48 and 72 hrs of incubation. ⁄ denotes P < 0.05 or less compared to untreated medium
(n = 8).
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coatings were the most fitting for further in vivo tests in rats.
Fig. 7 shows low- and high-magnification images of day 3 H&E-
stained sections of tissue that surrounded Tygon tubing that waseither bare or had 90% porous coatings with either 0.7 or 0 wt.%
Dex. The Dex-loaded coatings showed decreased immune cell infil-
tration to the implant site when compared to Dex-free porous
coatings and the bare controls. Moreover, the acute inflammatory
Fig. 7. Anti-inflammatory action of Dex-loaded porous coatings on the wound-healing response to glucose sensor implantation over a 3-day period. Implants were inserted in
the dorsum of rats and explanted 3 days later. Dex-loaded implants show a decreased inflammatory response when compared to Dex-free implants. (A) Low-magnification
H&E photomicrographs at day 3 (scale bar = 200 lm). (B) Corresponding high-magnification H&E photomicrographs of the top region of the implant at day 3 (scale
bar = 100 lm). (n = 3.).
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tude to that of the positive Tygon controls.4. Discussion
Tissue-associated anomalies with implanted glucose sensors
have been an area of concern for many years. These effects can
begin immediately following implantation or can arise during the
‘‘break-in period’’ that occurs during the first few days following
sensor insertion. During this time, the sensor is presented with
an unstable microenvironment characterized by immune cell infil-
tration, inflammation and formation of a granulation tissue. Strat-
egies for improving in vivo sensor performance include
development of new biomaterials and localized drug delivery for
resisting biofouling, attenuating inflammation, and increasing vas-
cularization of the foreign body capsule [17,25,26,29].
Previously, we reported porous polyester coatings deployed at
the tips of needle-type glucose sensors that increased vasculari-
zation and perfusion of the tissue–sensor interface; however,
implanted sensors succumbed to inflammation and immune cell
infiltration, resulting in early and pronounced signal reduction
[27]. We now employ a segmented polyurethane in order to
release the moderately hydrophobic anti-inflammatory glucocor-
ticoid Dex from the porous coatings. The present study charac-
terized the physical properties and drug-releasing properties of
the porous coatings, the bioactivity of the Dex released from
porous coatings, and the effect of these porous coatings on sen-
sor performance.
The porous Dex-loaded Tecoflex 93A coatings described herein
have a tunable microstructure. Pore size was controlled by sieving
ammonium bicarbonate particulates to a desired size range of 50–
75 lm. Immersing particulate-containing polymer coatings in a
heated water bath generated pores with sizes in the upper end of
the sieved salt particle size range (Table 2). Micro-CT generated
void volume renderings showed a mostly interconnected pore
structure that was most pronounced in coatings with high porogen
content (Fig 2). Moore et al. similarly demonstrated that increasing
the concentration of leachable sodium chloride particulates inpolyester scaffolds for bone tissue engineering resulted in
increased scaffold void volume and pore interconnectivity [30,31].
The poration step caused between 13% and 28% of the originally
loaded Dex to be lost from the polymer coating (Table 4). The larg-
est Dex loss occurred for the specimens with the highest polymer
surface area and wt.% Dex payload (90% porosity and 2.9 wt.% Dex).
Dex loss during poration can be attributed to increased specimen
porosity, the steep concentration gradient imposed on the coatings
during salt-leaching/gas-foaming fabrication steps, and heat-
induced enhanced drug and polymer chain mobility [32]. DSC
showed that there was no evidence of crystallized Dex present in
porous coatings (Fig. 3), indicating that Dex was molecularly dis-
solved within the polyurethane matrix.
Dex-loaded porous coatings exhibited a fast initial release fol-
lowed by a slower secondary release characteristic of monolithic
drug delivery from a polymer matrix (Fig 4). Daily Dex release from
coatings over the 15-day release period was within the therapeutic
rage for the treatment of localized acute inflammation (Table 3).
Interestingly, changes in coating porosity (surface area) did not sig-
nificantly affect drug release rates. Therefore, the high drug pay-
load of Dex over a short delivery window (2 weeks) cannot be
attributed to just simple diffusion of a small molecule drug
through a thin and highly porous surface [33,34]. Tecoflex93A is
a segmented polyurethane comprised of soft microdomains of
poly(tetramethylene oxide) and hard crystalline microdomains of
bis(4-isocyanatocyclohexyl)methane (H12MDI) and 1,4-butanediol.
As a non-polar drug, Dex preferentially interacts with the amor-
phous soft microdomains of the polyurethane; these regions serve
as drug reservoirs while empty hard crystalline microdomains act
as channels for drug release [35,36]. Similar results were reported
by Gupta et al. [33], where the small molecule hydrophobic drug,
dapivirine, was released from Tecoflex  rings for vaginal drug
delivery applications. This study also showed that Dex release from
the rings was fast and did not follow first-order release kinetics.
In vitro sensor responses to glucose challenge studies (Table 4
and Fig. 5) showed that sensor response was not hindered by
90% porous coatings. Signal lag and attenuation in low-porosity
coatings can be attributed to the increased thickness, decreased
pore interconnectivity and reduced total void volume. Functional
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sors with highly porous thick coatings (>200 lm) had elevated
response times and diminished signal when compared to bare sen-
sors. This effect was ascribed to the augmented migration distance
required for glucose to reach the sensor surface. Dex release from
coatings also did not interfere with sensor functionality (Fig. 5b).
Studies by other groups utilizing glucose oxidase based sensors
did not show signal fluctuations while functioning within the pres-
ence of locally released Dex [11,37,38]. Based on signal attenuation
and lag times, only 90% porous coatings were used for in vitro Dex
bioactivity and dose response.
The anti-inflammatory mechanism of Dex has been mostly
associated with regulation of cytokine production and reduced
metabolic activity of immune cells [24]; however, it has recently
been highlighted that Dex may also control inflammatory and
repair tissue responses by preferentially inducing apoptosis of
active inflammatory cells (monocytes, macrophages, T cells), while
protecting against apoptotic signals in cells involved in tissue
repair (epithelial cells and fibroblast) [21,39]. Consequently the
apoptotic monocyte assay reported by Schmidt et al. [21] was used
to show that Dex released from 90% porous coatings had a dose-
dependent therapeutic effect on immune cells in culture, and that
this effect was retained after the heat processing during the gas-
foaming/salt-leaching step.
In the Schmidt assay the Annexin-V protein preferentially
binds to the PS receptor, which is externalized on the surface
during early cell apoptosis. Annexin-V binding can therefore be
used as a marker for apoptosis detection on individual cells.
Dex released from coatings proved to be capable of inducing
apoptosis in a time- and dose-dependent manner (Fig. 6). Both
increasing the Dex payload of coatings and increasing the expo-
sure time to Dex increased the number of monocytes positive
for Annexin-V. Media samples made from Dex-free porous coat-
ings also did not show enhanced Annexin-V uptake, highlighting
the role of Dex as an apoptotic regulator of peripheral blood
derived human monocytes.
Pilot animal studies were performed to determine whether por-
ous coatings with payloads of 0.7, 1.4 and 2.9 wt.% Dex would elicit
an anti-inflammatory repose in rodents without any apparent sys-
tem effects. Not surprisingly, highly porous coatings with 0.7 wt.%
Dex loading were best suited for in vivo deployment since they
were able to suppress inflammation locally, while still allowing
for adequate immune function at distant sites. This formulation
initially delivers 30 lg per day of Dex (Table 3), which is within
the range of the recommended effective Dex daily dosage [11].
Coatings were further tested in a 3-day pilot study to determine
Dex’s effects on wound healing. Tygon tubing was chosen for
implantation instead of non-functional glucose sensors because
hydrogen peroxide builds up in the subcutaneous space adjacent
to the glucose oxidase present on non-functional sensors. In fully
functional sensors, the applied voltage quickly breaks down the
hydrogen peroxide generated by glucose oxidase before it can
accumulate. In our study, implant sites with Dex-free porous coat-
ings and bare Tygon controls showed a strong inflammatory
responses with dense fields of polymorphonuclear leukocytes,
monocytes and macrophages surrounding the implants. In con-
trast, Dex-loaded coatings showed a noticeably attenuated
response with fewer immune cells surrounding the implant. These
results demonstrate that Dex released from coatings is not only
bioactive but also capable of mediating the immune response to
sensor implantation.
Prior studies have shown that local Dex delivery is able to
improve sensor performance past the ‘‘break-in period’’ by
decreasing leukocyte migration and inflammation at the implant
site [19,22,23,25,38]. However, when Dex is delivered over the
long-term (>1 month) the drug can act as an angiostatic agentleading to reduced microvessel density, vasodilation, and increased
vascular permeability at the implant site.
The textured coatings presented delivered the majority of the
Dex payload over the initial week in vitro. This release is suitable
to take sensors though the break-in period, while the topographical
cues presented by the textured surface are intended to activate
endothelial cells to start the neovascularization process. Although
we demonstrated the short-term in vivo anti-inflammatory effect
of coatings, more exhaustive in vivo testing is necessary to fully
understand their potential as a platform to extend and improve
the functionality of implanted sensors.
The findings reported in this study show a system capable of
modulating the early stages of foreign body response to an
implant. Nevertheless, the integration of Dex-releasing porous
coatings into commercially available glucose-sensing platforms
faces significant regulatory challenges. As a combination product,
the system would require rigorous testing before it can reach the
diabetic patient population [40]. Commercial enterprises have in
turn resorted to the use of novel algorithms and recalibration
schemes to extend the in vivo functionality of continuous glucose
sensors [41,42].
Glucose-sensing systems have on occasion reported measure-
ments for up to several months in vivo [43]; however, glucose
readings from these studies are still heavily dependent on numer-
ical analysis and not sufficiently accurate clinically to pass regula-
tory approval and cannot be used as the sole means for programed
insulin delivery [44,45]. Therefore, the implementation of biomate-
rial and drug-delivery strategies to extend sensor function should
continue to be explored. Approaches such as localized Dex release
and delivery of topographical cues from the sensor surface could
drive the generation of a desirable tissue microenvironment that
could result in extended in vivo sensor functionality.5. Conclusions
Highly porous Dex-loaded coatings were fabricated by the gas-
foaming/salt-leaching technique. The coatings had a controlled
pore size and interconnected microstructure. A therapeutic dose
of Dex was loaded into coatings and proved to be in a molecularly
dissolved state. Dex release from coatings showed a typical initial
fast release followed by a steady release with a high dependency
on drug loading over a 15-day period. Porosity did not affect over-
all Dex release kinetics; however, decreasing coating porosity
increased sensor signal lag-time and attenuation. Therefore, 90%
porous Dex-releasing coatings were determined to be best for bio-
activity testing. Dex released from coatings was able to induced
apoptosis of human-derived peripheral blood monocytes in a time-
and dose-dependent manner. A pilot animal study over a 3-day
period confirmed that Dex released from coatings is capable of
mediating the acute inflammatory response of tissue surrounding
implants. Future work will focus on further in vivo testing of these
coatings, which will allow us to fully assess if the combinatorial
strategy of anti-inflammatory drug release and delivery of topo-
graphical cues from coatings could encourage tissue ingrowth
and angiogenesis while reducing the immune response to
implanted sensor leads.Acknowledgments
This work was funded by NIH grant DK 54932 (W.M.R.). We
gratefully acknowledge Medtronic Inc. for kind donation of Mini-
Med SOF-SENSOR™ glucose sensors, MiniLink™ transmitters,
Transmitter Utility software package, and for a Medtronic Gradu-
ate Fellowship (S.V.H.). The authors would like to thank our Duke
Colleagues: Charles S. Wallace for helpful technical discussions,
4638 S.G. Vallejo-Heligon et al. / Acta Biomaterialia 10 (2014) 4629–4638Michelle Gignac, James Thostenson for assistance with the SEM
andmicro-CT instruments; Jinny Cho and Alina Bocio for assistance
with histological stains, and members of the Needham Lab for
assistance with DSC. We also thank Patrick Kaiser from the Univer-
sity of Utah, and Lubrizol, Inc. for donation of Tecoflex polymers.
Appendix A. Figures with essential color discrimination
Certain figures in this article, particularly Figs. 1, 2, 5 and 7 are
difficult to interpret in black and white. The full color images can
be found in the on-line version, at http://dx.doi.org/10.1016/
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